Author Topic: Nature (December 1, 2016) Supplement on MS  (Read 108 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
Nature (December 1, 2016) Supplement on MS
« on: March 28, 2017, 07:02:03 am »
The journal Nature issued a Supplement devoted to MS on December 1, 2016. Its articles are available:

http://www.nature.com/nature/outlook/multiple-sclerosis/

The special issue of this journal was supported by a grant from Hoffmann-LaRoche.

« Last Edit: March 28, 2017, 07:09:54 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
Caution about the Nature Outlook issue on MS
« Reply #1 on: March 29, 2017, 12:14:15 pm »
I've been wondering about this Outlook issue from Nature, which seems to be highly respected as a scientific journal.

It seems that Nature issues Outlook as a special, somewhat "dumbed down" periodical from time to time. Here is what Nature says about it:

Quote
Nature Outlooks tackle topics of scientific, clinical and societal interest, giving a comprehensive picture of the current state of knowledge and the hottest areas of research. They present news features written by top science journalists and commentary pieces from leading academic and industry thinkers. A Nature Outlook might focus on a disease, technological innovation or a field of particularly intense scientific progress. Outlooks target a generalist, scientifically literate audience, while maintaining Nature’s strong evidence-based editorial values. As such, Outlooks offer a unique opportunity for sponsors to report their scientific advances in the pages of Nature alongside relevant, independent and accessible content.

Couched in this paragraph is "a unique opportunity for sponsors to report their scientific advances in the pages of Nature alongside relevant, independent and accessible content."

I was perturbed when I saw that the content of this entire issue seems like boilerplate MS information, some of it highly questionable. The section about diet, in particular, isn't very trustworthy information.

The article on stem cells gives a very negative view of this treatment.

On the other hand, Ocrevus is described in glowing terms in the section entitled "Therapies: Progressive steps."

The sponsor of this issue of Nature Outlook, as mentioned earlier, is Hoffmann-LaRoche. The issue is dated December 2, 2016--nicely timed to precede the anticipated FDA approval of Ocrevus.

Hoffmann-LaRoche is the maker of Ocrevus.

MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
72 Views
Last post November 09, 2016, 08:29:09 am
by agate
0 Replies
60 Views
Last post December 01, 2016, 02:43:42 pm
by agate
0 Replies
218 Views
Last post December 08, 2017, 02:51:04 pm
by agate
0 Replies
153 Views
Last post August 04, 2019, 09:38:00 pm
by agate
0 Replies
28 Views
Last post February 24, 2021, 09:06:29 pm
by agate